DATASHEET
Host:
Rabbit
Target Protein:
GABRG2 Ser366
Modification Site:
Ser366
Clonality:
Polyclonal
Isotype:
IgG
Entrez Gene:
2566
Source:
KLH conjugated synthetic phosphopeptide derived from human GABRG2 around the phosphorylation site of Ser366
Purification:
Purified by Protein A.
Storage Buffer:
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage:
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Background:
GAD-65 and GAD-67, glutamate decarboxylases, function to catalyze the production of GABA (gamma-aminobutyric acid). In the central nervous system, GABA functions as the main inhibitory transmitter by increasing a Cl- (chloride) conductance that inhibits neuronal firing. GABA has been shown to activate both ionotropic (GABAA) and metabotropic (GABAB) receptors, as well as a third class of receptors called GABAC. The ?subunit of GABAA receptors are important for benzodiazepine binding and modulation of GABA-mediated Cl- current. GABAA R? is a 467 amino acid mulit-pass membrane protein localized to the postsynaptic cell membrane. Present as a pentamer with other GABAA receptor chains (Alpha, Beta, Gamma, Delta and Epsilon), the GABAA ligand-gated Cl- channels selectively complex with D5DR to enable mutual inhibitory functional interactions between the two receptor systems. Defects in the gene encoding GABAA R Gamma 2 have been found to be the cause of childhood absence epilepsy type 2, familial febrile convulsions type 8, generalized epilepsy with febrile seizures plus type 3 and severe myoclonic epilepsy in infancy.
VALIDATION IMAGES
Mouse Cerebrum lysates probed with phospho-GABRG2 (Ser366) Polyclonal Antibody, Unconjugated (bs-12079R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.
Lane 1: Rat Cerebrum lysates; Lane 2: Mouse spinal cord lysates probed with phospho-GABRG2 (Ser366) Polyclonal Antibody, Unconjugated (bs-12079R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.